Clinical Trial Update: Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice

View source ↗

Summary

Completed clinical trial evaluating real-world retention of first- and second-line adalimumab, etanercept, and infliximab as biotherapies for rheumatoid arthrit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ENBREL (etanercept)
• Humira (adalimumab)
• Remicade (infliximab)

Snippet

Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Status: COMPLETED